4,121
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Lung Deposition Using the Respimat® Soft Mist™ Inhaler Mono and Fixed-Dose Combination Therapies: An In Vitro/In Silico Analysis

, , , &
Pages 91-100 | Received 21 Aug 2020, Accepted 12 Nov 2020, Published online: 11 Dec 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Varsha Komalla, Chun Yuen Jerry Wong, Imco Sibum, Bernhard Muellinger, Wietze Nijdam, Vishal Chaugule, Julio Soria, Hui Xin Ong, Nicolas A. Buchmann & D. Traini. (2023) Advances in soft mist inhalers. Expert Opinion on Drug Delivery 20:8, pages 1055-1070.
Read now
Ayca Yildiz Pekoz, Ozlem Akbal Dagistan, Hanan Fael, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Muge Serhatli, Gamze Cakirca, Saban Tekin, Leyla Semiha Sen, Mustafa Sevim, Lutfiye Mulazimoglu Durmusoglu & Berrak C. Yegen. (2022) Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis. Drug Delivery 29:1, pages 2846-2854.
Read now
Donald A Mahler, Andrea Ludwig-Sengpiel, Gary T Ferguson, Alberto de la Hoz, John Ritz, Asif Shaikh & Henrik Watz. (2021) TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 2455-2465.
Read now

Articles from other publishers (5)

Roland Buhl, Michael Dreher, Muriel Mattiucci-Guehlke, Rachel Emerson-Stadler, Sebastian Eckhardt, Christian Taube & Claus F. Vogelmeier. (2023) EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS. Advances in Therapy 40:7, pages 3263-3278.
Crossref
Warren H. Finlay, Dino J. Farina, Scott Tavernini & Andrew R. Martin. (2022) In Vitro Estimation of Tracheobronchial and Alveolar Doses Using Filters. Frontiers in Drug Delivery 2.
Crossref
Jeffry Weers. (2022) Suboptimal Inspiratory Flow Rates With Passive Dry Powder Inhalers: Big Issue or Overstated Problem?. Frontiers in Drug Delivery 2.
Crossref
Paola Rogliani, Beatrice Ludovica Ritondo, Ermanno Puxeddu, Mario Cazzola & Luigino Calzetta. (2021) Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review. Respiratory Medicine 189, pages 106639.
Crossref
V. V. Arkhipov. (2021) Respimat as the new standard for inhalation therapy devices. Meditsinskiy sovet = Medical Council:16, pages 32-37.
Crossref